In this article, we will list the 5 Best Longevity Stocks to Buy Now. Please visit 7 Best Longevity Stocks to Buy Now if you would like to see the extended list and the methodology behind it.
5. UnitedHealth Group Incorporated (NYSE:UNH)
On June 8, 2026, JPMorgan raised the firm’s price target on UnitedHealth Group Incorporated (NYSE:UNH) to $466 from $420 and maintained an Overweight rating on the shares. JPMorgan updated its healthcare service models.
On the same day, Mizuho raised the firm’s price target on UnitedHealth Group Incorporated (NYSE:UNH) to $460 from $440 and maintained an Outperform rating on the shares. Mizuho said the managed care sector is entering a “more stable and predictable” policy environment, with policy-related surprises likely to moderate from the elevated levels of the past three years. The firm said this should let investors focus on company fundamentals, pricing recovery, and embedded earnings power.
On June 4, 2026, BofA analyst Kevin Fischbeck upgraded UnitedHealth Group Incorporated (NYSE:UNH) to Buy from Neutral with a price target of $450, up from $420. Fischbeck said incoming data points make it harder to view the strong Q1 as purely tied to weak flu and storms, and said UnitedHealth should lead a broader managed care rally if utilization trends continue to moderate.
UnitedHealth Group Incorporated (NYSE:UNH) operates as a health care company in the United States and internationally.
4. Novo Nordisk A/S (NYSE:NVO)
On June 7, 2026, Novo Nordisk A/S (NYSE:NVO) presented Phase 3 results from its Reimagine 1-3 trials, which showed significant reductions in HbA1c and weight in adults with type 2 diabetes. The Reimagine trials met their primary endpoints, showing significant HbA1c reductions, and met their confirmatory secondary endpoints for bodyweight reduction. The data were presented during a late-breaking symposium at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, alongside publication of the Reimagine 1 and 2 results in The Lancet Diabetes & Endocrinology and the Reimagine 3 results in The Lancet.
Also on June 7, Novo Nordisk A/S (NYSE:NVO) announced new real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide 1 mg. The analysis compared escalation to semaglutide 2 mg with switching to tirzepatide. By one year, both groups were associated with similar proportions of patients achieving HbA1c of less than 7%, while patients on semaglutide 2 mg had a statistically significantly higher event rate for achieving weight loss greater than or equal to 5%.
Novo Nordisk A/S (NYSE:NVO) also presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS trials at the ADA Scientific Sessions, highlighting data on semaglutide across weight-related conditions. Senior medical director Andrea Traina said the analyses add to the clinical evidence for semaglutide across obesity, cardiovascular disease, and metabolic dysfunction-associated steatohepatitis.
Novo Nordisk A/S (NYSE:NVO) researches, develops, manufactures, and distributes pharmaceutical products.
3. Gilead Sciences, Inc. (NASDAQ:GILD)
On June 5, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) applauded the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. CEO Daniel O’Day said South Africa is “at the heart of global efforts to end HIV,” and that Gilead is working with country leadership, the Global Fund, and the U.S. State Department through PEPFAR to bring lenacapavir to communities most in need ahead of a broader rollout of generic versions.
On June 2, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase 3 results in primary biliary cholangitis showing that Livdelzi led to significantly more patients achieving normalization of alkaline phosphatase, or ALP, compared with placebo after 52 weeks. The primary endpoint was defined as ALP less than or equal to 1.0 upper limit of normal and a greater than or equal to 15% decrease from baseline. Cynthia Levy of the University of Miami Miller School of Medicine said the IDEAL results further support the efficacy and safety profile of Livdelzi.
On May 27, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) shared post hoc analysis data from the ongoing Phase 3 ASSURE study showing high and sustained ALP normalization rates in people with primary biliary cholangitis. Among 50 participants, 83% of evaluable participants achieved composite ALP normalization at 12 months, while 74% achieved the same endpoint at 24 months. Gilead said Livdelzi was generally well tolerated, with no treatment discontinuations due to adverse events and no new safety signals observed with up to two years of follow-up.
Gilead Sciences, Inc. (NASDAQ:GILD) discovers, develops, and commercializes medicines in areas of unmet medical need in the United States, Europe, and internationally.
2. Abbott Laboratories (NYSE:ABT)
On June 7, 2026, Abbott Laboratories (NYSE:ABT) announced new data showing that diabetic ketoacidosis, or DKA, “remains an important” but often undetected health concern for people with both Type 1 and Type 2 diabetes. The findings, shared at the American Diabetes Association’s 86th Scientific Sessions, showed sharp increases in DKA-related hospitalizations across all age groups nationwide. Mahmood Kazemi, chief medical officer for Abbott’s diabetes care business, said the data show that preventing DKA starts with recognizing risk earlier.
On May 27, 2026, Abbott Laboratories (NYSE:ABT) announced that it secured the CE Mark for its dual glucose-ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, giving users real-time visibility into glucose levels and rising ketones that can lead to a DKA emergency. Abbott said it plans to begin launching Libre Duo systems in select European countries later this year.
Also on May 27, Abbott said the American Cancer Society released updated colorectal cancer screening guidelines that reaffirm Cologuard and Cologuard Plus as preferred noninvasive screening options for adults aged 45 and older at average risk for CRC.
Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products worldwide.
1. Pfizer Inc. (NYSE:PFE)
On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is now indicated in the U.S. for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients 6 years and older with hemophilia A with or without factor VIII inhibitors, or hemophilia B with or without factor IX inhibitors.
On June 7, 2026, Pfizer Inc. (NYSE:PFE) presented detailed Phase 2b results for berobenatide, an investigational monthly GLP-1 receptor agonist peptide, at the 86th Scientific Sessions of the American Diabetes Association. The company said the VESPER-1, 2, and 3 studies provided proof of concept for berobenatide as a potential first-in-class monthly GLP-1 RA peptide, showed favorable tolerability, and highlighted potential advantages from monthly delivery and a 0.5 mL injection volume.
On May 31, 2026, Pfizer Inc. (NYSE:PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 Breakwater trial. Pfizer said median progression-free survival was nearly doubled with the BRAFTOVI combination regimen versus the comparator.
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 High Growth Stocks to Buy and Hold for the Next Decade and 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
